Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Co ...